A Randomized Placebo-Controlled Trial of Saccharomyces boulardii in Combination With Standard Antibiotics for Clostridium difficile Disease

JAMA: The Journal of the American Medical Association

Volumn 271, Issue 24, 1994, Pages 1913-1918

  Mcfarland, Lynne V ^a   Surawicz, Christina M ^a   Elmer, Gary W ^a   Moyer, Kris A ^a   Melcher, Sally A ^a   Fekety, Robert ^b   Bowen, Karen E ^b   Cox, Jenny L ^b   Noorani, Zehra ^b   Harrington, Gregory ^b   Rubin, Moshe ^b   Greenwald, David ^b   Greenberg, Richard N ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; CEPHALOSPORIN DERIVATIVE; METRONIDAZOLE; PENICILLIN DERIVATIVE; PLACEBO; RIFAMPICIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LACTOBACILLUS CASEI; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SACCHAROMYCES BOULARDII; THIRST;

EID: 0028226085     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1994.03510480037031     Document Type: Article

References (36)

1. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA. 1993;269:71-75.
2. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204-210.
3. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis. 1992;166:561-567.
4. Brown EB, Talbot GH, Axelrod P, Provencher M, Hoegg C. Risk factors for Clostridium difficile toxin—associated diarrhea. Infect Control Hosp Epidemiol. 1990;11:283-290.
5. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile—associated diarrhea and colitis in adults. Arch Intern Med. 1986;146:95-100.
6. McFarland LV. Diarrhea acquired in the hospital. In: Giannella RA, ed. Acute Infectious Diarrhea. Philadelphia, Pa: WB Saunders Co; 1993:563-577.
7. Mulligan ME, Rolfe RD, Finegold SM, George WL. Contamination of a hospital environment by Clostridium difficile. Curr Microbiol. 1979;3:173-175.
8. Bender BS, Laughon BE, Gaydos C, et al. Is Clostridium difficile endemic in chronic-care facilities? Lancet. 1986;2:11-13.
9. Bennett RG, Greenough WB III. Clostridium difficile diarrhea: a common—and overlooked— nursing home infection. Geriatrics. 1990;45:77-87.
10. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med. 1989;86:15-19.
11. Walters BAJ, Roberts R, Stafford R, Seneviratne E. Recurrence of antibiotic associated colitis: endogenous persistence of C difficile during vancomycin therapy. Gut. 1983;24:206-212.
12. Bartlett JG, Tedesco FJ, Shull S, Lowe B, Chang T. Symptomatic recurrence after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology. 1980;78:431-434.
13. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology. 1985;89:1038-1045.
14. Kimmey MB, Elmer GW, Surawicz CM, McFarland LV. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig Dis Sci. 1990;35:897-901.
15. Young G, McDonald M. Antibiotic-associated colitis: why do patients relapse? Gastroenterology. 1986;90:1098-1099.
16. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994; 330:257-262.
17. Nord CD, Edlund C. Impact of antimicrobial agents on human intestinal microflora. J Chemother. 1990;2:218-237.
18. Roberts MC, McFarland LV, Mullany P, Mulligan ME. Characterization of the genetic basis of antibiotic resistance in Clostridium difficile. J An timicrob Chemother. 1994;33:419-429.
19. Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos. 1989;10:353-364.
20. Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res. 1993; 10:1615-1619.
21. Berg R, Bernasconi P, Fowler D, Gautreaux M. Inhibition of Candida albicans translocation from the gastrointestinal tract of immunosuppressed mice by oral treatment with Saccharomyces boulardii. J Infect Dis. 1993;168:1314-1318.
22. Boddy AV, Elmer. GW, McFarland LV, Levy RH. Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats. Pharm Res. 1991;8:796-800.
23. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, Van Bell G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989; 96:981-988.
24. McFarland LV, Bernasconi P. A review of a novel biotherapeutic agent: Saccharomyces boulardii. Microb Ecology Health Dis. 1993;6:157-171.
25. Elmer GW, McFarland LV. Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother. 1987;31: 129-131.
26. Surawicz CM, McFarland LV, Elmer G, Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol. 1989;84:1285-1287.
27. George WL, Volpicelli NA, Stiner DB, et al. Relapse of pseudomembranous colitis after vancomycin therapy. N Engl J Med. 1979;301:414-415.
28. Johnson LL, McFarland LV, Dearing P, Raisys V, Schoenknect FD. Identification of Clostridium difficile in stool specimens by culture-enhanced gasliquid chromatography. J Clin Microbiol. 1989;27: 2218-2221.
29. Bowman RA, Riley TV. Isolation of Clostridium difficile from stored specimens and comparative susceptibility of various tissue cell lines to cytotoxin. FEMS Microbiol Lett. 1986;34:31-35.
30. Breslow NE, Day NE. Statistical Methods in Cancer Research. Lyon, France: International Agency for Research on Cancer; 1987;2:107-109.
31. Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet. 1987;2:1519.
32. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1:1156-1160.
33. Schwann A, Sjolin S, Trottestam U, et al. Relapsing Clostridium difficile diarrhoea by administration of a nontoxigenic strain. Eur J Clin Microbiol. 1987;6:51-53.
34. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993;104:1108-1115.
35. Krammer M, and Karbach U. Antidiarrheal action of the yeast Saccharomyces boulardii in the rat small and large intestine by stimulating chloride absorption. Z Gastroenterol. 1993;31(suppl 4): 73-77.
36. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C difficile—associated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990;162:678-684.